Effect of telmisartan on serum lipid profile in patients with hypertension and dyslipidemia

Hypertension and dyslipidemia are two major risk factors for cardiovascular disease and they commonly occur together. Management of dyslipidemia in a hypertensive patient significantly reduces the total cardiovascular risk.Telmisartan is an Angiotensin receptor blocker with a partial agonistic action on PPAR-γ. In the present study, the effect of Telmisartan on serum Lipid Profile was evaluated in hypertensive patients who also have associated Dyslipidemia and also the efficacy of Telmisartan in reducing systolic and diastolic BP was assessed in these patients. Materials and Methods: A total of 50 outpatients from the medical outpatient department of Gandhi Hospital, Secunderabad, were enrolled into the study. These patients had grade I essential Hypertension and mild dyslipidemia. After the study period of 24 weeks, the efficacy of Telmisartan in reducing serum lipid profile was evaluated apart from its effect on reducing systolic and diastolic BP.

Telmisartan was very effective in reducing serum triglycerides (27%t, P<0.01), VLDL-C (27%t, P<0.01), LDL-C (22%t, P<0.01). It also decreased serum cholesterol by 16% (P<0.01). HDL-C increased by 14% (P<0.05). Telmisartan in a dose of 40–80 mg/day, significantly reduced both systolic BP by 18% (P<0.01) and diastolic BP by 12%(P<0.01)

In our study, Telmisartan proved to be effective not only in controlling BP, but had a favorable effect on lipid profile also So, in conclusion, all the patients with uncomplicated Hypertension and mild dyslipidemia can be effectively treated with Telmisartan.